1999
DOI: 10.1016/s0015-0282(98)00513-5
|View full text |Cite
|
Sign up to set email alerts
|

Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

9
45
0
5

Year Published

2001
2001
2007
2007

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 92 publications
(59 citation statements)
references
References 51 publications
9
45
0
5
Order By: Relevance
“…10 -12 Treatment of postmenopausal women with estrogens reduces plasma levels of adhesion molecules and other markers of endothelial activation. 13,14 In hypercholesterolemic rabbits, estradiol both inhibits monocyte adhesion and decreases vascular cell adhesion molecule (VCAM)-1 expression. 15 Estradiol also inhibits VCAM-1 expression in cultured endothelial cells through interference of NF-B activity.…”
mentioning
confidence: 99%
“…10 -12 Treatment of postmenopausal women with estrogens reduces plasma levels of adhesion molecules and other markers of endothelial activation. 13,14 In hypercholesterolemic rabbits, estradiol both inhibits monocyte adhesion and decreases vascular cell adhesion molecule (VCAM)-1 expression. 15 Estradiol also inhibits VCAM-1 expression in cultured endothelial cells through interference of NF-B activity.…”
mentioning
confidence: 99%
“…Recently, it was shown that MCP-1, a particularly important mediator and amplifier of atherogenic signals, was downregulated after introduction and upregulated after discontinuation of 17b-estradiol; this observation was reproduced by others with conjugated equine estrogens [41,42]. Downregulation of inflammatory and vasoactive markers by different types, dosages and routes of HRT application has been demonstrated for cell adhesion molecules -such as ICAM-1, VCAM-1 and E-selectin [43 -54] -TNF-a [55 -57], vascular endothelial growth factor [58] and endothelin-1 [59][60][61][62][63][64][65][66][67]. As an endotheliumderived relaxing factor with anti-atherosclerotic and antiinflammatory properties, nitric oxide (NO) has received particular attention.…”
mentioning
confidence: 74%
“…The effect appeared to be strongest with unopposed conjugated equine estrogen [75] and was possibly ameliorated by the addition of a gestagen [76]. Conversely, six randomized trials with 17b-estradiol (three with oral [43,64,77], two with transdermal administration [78,79], and one comparing both [80]) and four non-randomized studies [53,81 -83] found reduced or unaffected CRP levels with either transdermal or oral combined regimens. Apparently, unopposed 17b-estradiol also raised CRP in a dose-dependent manner [77,80,82].…”
mentioning
confidence: 99%
“…Basal release of NO is higher in females than in males, and oophorectomy diminishes both circulating-estradiol concentration and basal release of NO to levels seen in males (Hayashi et al, 1992), thus offering an explanation for the protective effect of estradiol against the development of atherosclerosis. In agreement with experimental evidence, estrogen replacement therapy in postmenopausal women improves the impaired endothelial-dependent relaxation (Gerhard et al, 1998), but this evidence has been recently questioned (Van Baal et al, 1999). However, estrogens also have adverse effects on the reproductive system of females (Grady et al, 1995) and males (Robinson et al, 1963) that limits their therapeutic use.…”
mentioning
confidence: 88%